These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8477906)

  • 1. Development of a rapid and sensitive chromogenic heparin assay for clinical use.
    Wagenvoord RJ; Hendrix HH; Kolde HJ; Hemker HC
    Haemostasis; 1993; 23(1):26-37. PubMed ID: 8477906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
    Mouton C; Calderon J; Janvier G; Vergnes MC
    Thromb Res; 2003; 111(4-5):273-9. PubMed ID: 14693175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated determination of heparin with chromogenic substrates.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):184-94. PubMed ID: 6735276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma.
    Abildgaard U; Larsen ML
    Thromb Res; 1984 Aug; 35(3):257-66. PubMed ID: 6547786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration.
    Lyon SG; Lasser EC; Stein R
    Thromb Haemost; 1987 Oct; 58(3):884-7. PubMed ID: 2448889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
    Zammit A; Dawes J
    Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An improved heparin assay which is insensitive to platelet factor 4.
    Fickenscher K; Buckler U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):873-8. PubMed ID: 2483705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin and antiheparin in young children. 1. Report: development of a method for determining heparin and antiheparin in the antithrombin-thrombin system].
    Domula M; Weissbach G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(5):808-23. PubMed ID: 6188669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a simple chromogenic factor VIII assay for clinical use.
    Wagenvoord RJ; Hendrix HH; Hemker HC
    Haemostasis; 1989; 19(4):196-204. PubMed ID: 2509307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated spectrophotometric heparin assays. Comparison of methods.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):195-204. PubMed ID: 6735277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a sensitive and rapid chromogenic factor IX assay for clinical use.
    Wagenvoord R; Hendrix H; Tran T; Hemker HC
    Haemostasis; 1990; 20(5):276-88. PubMed ID: 2127037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins.
    Williams EC; Huppert BJ; Asakura S
    J Lab Clin Med; 1992 Jul; 120(1):159-67. PubMed ID: 1377216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.
    Alban S; Lühn S; Schiemann S
    Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A colorimetric assay for plasma antithrombin III using a new synthetic peptide substrate (PS-915).
    Asai K; Asai M
    Clin Chim Acta; 1984 Dec; 144(2-3):163-71. PubMed ID: 6397281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238).
    Larsen ML; Abildgaard U; Teien AN; Gjesdal K
    Thromb Res; 1978 Aug; 13(2):285-8. PubMed ID: 567858
    [No Abstract]   [Full Text] [Related]  

  • 19. A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma.
    Warttinger U; Giese C; Harenberg J; Holmer E; Krämer R
    Anal Bioanal Chem; 2016 Nov; 408(28):8241-8251. PubMed ID: 27655335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
    Ponjee GA; Vader HL; de Wild PJ; Janssen GW; van der Graaf F
    Clin Chem; 1991 Jul; 37(7):1235-44. PubMed ID: 1855296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.